Professor Yaping Li has long been engaged in research in pharmaceutics, drug delivery technology, and R&D of new drug. He is a distinguished professor in Chinese Academy of Sciences (CAS), the member of European Academy of Sciences (EurASc, since 2025), the director of Center of Pharmaceutics in Shanghai Institute of Materia Medica (SIMM, CAS, since 2007), the head of Yantai Institute of Pharmaceutical Science (Yantai Branch of SIMM, since 2015), Fellow of the Royal Society of Chemistry (FRSC), Fellow of the International Academy of Advanced Materials (FIAAM), the Chairman of Nano-oncology Committee of Chinese Anti-Cancer Association (CACA, 2021-2024), the Vice Chairman of the Nanomedicine Committee of Chinese Pharmaceutical Association (CPA, 2015-2024), and the editorial board member of 6 international journals such as Pharmaceutics, APS B, AJPS, etc. He obtained PhD at Fudan University in China (2001), and postdoctoral training at University of Munich (LMU), Germany (2001-2002).

As a leader of the National Natural Science Foundation of China (NSFC) innovation group & the Ministry of Science and Technology (MOST) innovation team of key areas of China, Yaping Li is a recipient of the Outstanding Youth Science Foundation, Chief Scientist of 973 and National Key R&D Programs, National Leading Talent of Scientific Innovation. His work has earned him serval prestigious awards, including the Second Prize of the National Natural Science Award in China (2020), First prize of Shanghai Science and Technology Progress Award (2022). He has been recognized as one of the most preeminent pharmaceutical scientists in China by winning twice First Prize of Science and Technology Award of CPA (2015 and 2020), Wu Jieping Pharmaceutical Innovation Award (2022), Shanghai Science and Technology Elite, and Special Contribution Award of China Pharmaceutical Development Award.

Yaping Li authored over 280 publications in TOP journals such as Nat Nanotech, Sci Immunol, Nat Commun and Adv Mater, etc., with over 24000 citations, 24 ESI Highly Cited Papers, and an H-index of 85. He is recognized as a Highly Cited Scientist worldwide (Elsevier & Clarivate) since 2021. He ranks among the TOP 5 in the China Top 100 Academic Influence of Pharmacy Specialists list (Global Scholars Database) since 2021. He has led the R&D of over 60 pharmaceutical preparations, 21 of which are currently in clinical uses, with 16 in clinical trials. He has also established 9 national drug standards and authorized 85 patents.

BELIEF: Creating new drugs with better effects and less side-effect to relieve patients' suffering from diseases.